International Scholarly Research Notices / 2014 / Article / Tab 2

Clinical Study

Efficacy and Clinical Determinants of Antipsychotic Polypharmacy in Psychotic Patients Experiencing an Acute Relapse and Admitted to Hospital Stay: Results from a Cross-Sectional and a Subsequent Longitudinal Pilot Study

Table 2

Patients’ demographics and clinical variables in the longitudinal study.

AP + APAP Effect sizedf

Age (years)44.9 ± 10.248.2 ± 13.50.3840
Gender m/f9/1213/80.351
Age at onset (years)24.1 ± 9.429.6 ± 13.50.1929
Duration of disease (years)21.1 ± 7.421.1 ± 12.1 0.9729
Diagnosis (%)
(i) Schizophrenia9170.13
(ii) Schizoaffective11
(iii) Bipolar disorder type I62
(iv) Bipolar disorder NOS41
Comorbid diagnosis ( ):
(i) Mental retardation220.153
(ii) Cognitive impairment02
(iii) Alcoholism53
(iv) Personality disorder01
Psychotropic drugs (%)
(i) First generation antipsychotics21*10.002 : 16.044
(ii) Second generation antipsychotics2414
(iii) Mood stabilizers1518
(iv) Antidepressants22
(v) Benzodiazepines89
(vi) Anticholinergics12
Antipsychotic doses (in mg/day chlorpromazine equivalents)920.57 ± 400.09*450.66 ± 250.410.0001 : 4.3140

Here, we reported data on (i) demographics in AP + AP versus AP patients included in the longitudinal study; (ii) rates and distribution of psychiatric and organic comorbid diagnoses in AP + AP versus AP patients; (iii) rates and distribution of antipsychotic and non-antipsychotic psychotropic agents in AP + AP versus AP patients; (iv) antipsychotic doses (in mean mg/day chlorpromazine equivalents) in AP + AP versus AP patients. Demographic and pharmacological variables were compared by Student’s test. Diagnosis and antipsychotic distribution were compared by chi-square test. Significant values have been marked in bold and with an asterisk and given with effect size ( , ). df: degrees of freedom.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.